Hot Investor Profile: Corporate VC Arm of Global Dairy Corporation Seeks Seed to Series A Biotech Innovations for Human Health, Open to Various Deal Structures

An early-stage investment fund supporting innovation across human health, food, agriculture, and climate is backed by sole LP, one of the world’s largest dairy exporters and producer of human nutrition products. The fund brings experience and expertise across both investing & operating in the Food and BioTech, ClimateTech and AgTech sectors. Its operating model allows access into the nearly 100 years of capability, ingenuity, manufacturing and distribution experience within its parent corporation, while maintaining the agility and responsiveness to be a strong partner to start-ups and innovators in the space.

The fund typically invests in seed to Series A opportunities, though remains open to companies at later stages. The average check size ranges from $2M to $5M USD, with the ability to go beyond this. The fund is open to both leading and co-investing and will consider board positions on a case-by-case basis. The fund is actively seeking opportunities globally and is open to deal structures beyond equity investments, such as co-development and in-licensing, especially for technologies that align strategically with it parent corporation.

The fund is generally interested in technologies that use nutrients to improve human health, such as those targeting the microbiome, cognitive function, sleep, and more. Areas of interest include the microbiome, alternative ingredients, and the application of molecules and proteins. The fund places a strong emphasis on data. In terms of development stages, the fund is open to working with companies from the pre-clinical stage through all phases of clinical and commercial development. The fund does not have specific requirements for the company or management team. However, the fund seeks founding teams with passion and strong technical expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: Global PE Firm with UK and US Offices Seeking $10M to $30M Private Market Opportunities in Therapeutics, Medical Devices, and Diagnostics

Headquartered in London and New York with offices worldwide, a private equity firm managing ~$65M in assets under management (AUM). The firm invests in both public and private markets across various industries, with a healthcare-focused team dedicated to private market investments. Their average initial check size ranges from $10M to $30M, with follow-on investments expected. The firm has the ability to led, co-lead, or join a round as a syndicate member.

The firm is interested in opportunities in therapeutics, medical devices, and diagnostics. The firm is agnostic to subsectors and indications and is willing to consider orphan drugs. Within therapeutics, they prefer asset-forward companies but are open to platform companies with lead assets or drugs. Regarding the phase of development, the firm seeks clinical stage companies or companies that are no more than 6-9 months away from the clinical stage.

The firm doesn’t have specific requirements for companies’ management teams. The firm will consider board or observer seats on a case-by-case basis, but this is not a requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: Boston-Based Stage-Agnostic Boutique VC Investing in Healthcare Focused on Longevity and Aging-Related Technologies

A boutique venture capital firm headquartered in Boston with a global outreach and epicenter in Dubai has invested alongside Tier 1 VCs in 12 companies with 5 exits qualified as unicorns. The firm is stage-agnostic and can invest at any stage. With this said, check sizes are flexible and can range from $500K – $15M. Their capital comes mostly from qualified purchasers (investors) located in the MENA region at large and GCC region specifically. To date, the firm has invested in USA based companies.

The firm is focused on healthcare, energy, ICT and infotech and most recently data defined networks addressing the systems aging and longevity (and research at large) pain points. The firm has invested in medi-tech, health-tech and biotech in the past which includes but not limited to diagnostics, medical devices, therapeutics, and digital health. The firm invests within 4 pillars of longevity roadmap covering health span and lifespan namely: (a) preventative, (b) replacement, (c) biostasis, and (d) therapeutics and genetic engineering on the basis that they are targeting systems aging and longevity. The firm prefers a management team with domain expertise, past performance and PhD’s / higher educational pedigree.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Unlocking Global Fundraising Opportunities with RESI: From London to JPM 2025

By Joey Wong, Senior Investor Research Analyst, Hong Kong BD, LSN

Joey-New-Headshot

As the Life Science Nation (LSN) team continues to facilitate meaningful connections between early-stage startups and investors, the upcoming RESI conferences offer unparalleled opportunities to advance your fundraising efforts on a global scale. Whether you’re an emerging startup or an established company looking to expand your investor network, RESI conferences create a platform to engage directly with investors aligned with your sector and stage.

RESI London: December 4-6, 2024

RESI is excited to arrive in London for the first time, to the heart of the UK life science ecosystem, taking place at 11 Cavendish Square from December 4-6. This premier event will feature panels tailored to early-stage companies focused on sectors including seed funding, early-stage therapeutics, and medical devices. London’s robust life science community provides a rich backdrop for innovators to meet investors who are ready to support their vision.

RESI London Investor Panels
9AM
Seed Funds Panel
Investing in Innovation in the Earliest Stages
10AM
Early Stage Therapeutics Panel
Bringing the Newest Therapies to the Clinic
11AM
Medical Device Panel
Forward Looking Trends in Medical Device Innovations
Register for RESI London

RESI JPM 2025: January 13-15, 2025

Mark your calendar for the flagship RESI event during JPM Week in San Francisco, January 13-15, 2025, at the Marriott Marquis. RESI JPM 2025 will showcase a broad spectrum of panels, addressing critical sectors such as women’s health, oncology innovation, longevity investment, and more. The strategic timing of this conference places your company at the intersection of investor interest and the bustling energy of JPM Week.

RESI JPM Investor Panels
9AM
Corporate VC Panel
Firms Investing Beyond Financial Return
10AM
Women’s Health Panel
Investing in New Innovations in FemTech
11AM
Medical Device Panel
Forward Looking Trends in Medical Device Innovations
1PM
Pediatrics Panel
Advancing Treatments for Pediatric Patients
2PM
Big Pharma Panel
Strategies for Pre-Clinical & Early Clinical Assets
3PM
Oncology Innovation Panel
The Search for New Approaches to Diagnosing & Treating Cancer
4PM
Longevity Investment Panel
Opportunities and Priorities in Age-Related Disease Therapies
Register for RESI JPM

By attending RESI JPM, you’ll position your company at the center of one of the most impactful investor gatherings of the year. Each session offers a targeted look at the challenges and opportunities within these critical areas, providing actionable insights for both investors and innovators.

Extend Your Reach Across Global Ecosystems
With back-to-back conferences in London and San Francisco, RESI offers startups the chance to engage with a diverse range of investors, from family offices to big pharma and venture capitalists. Register today and accelerate your fundraising journey.

RESI-London-2024-1100px

RESI-SF-2025-Banner-1100px

Life Science Nation Expands Global Reach at BioJapan 2024 and The MedTech Conference

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
Max Braht, Business Development Manager, LSN

Max-Braht-HeadshotAs part of its continued global outreach, Life Science Nation (LSN) will be actively participating in two major international conferences this October: BioJapan 2024 (October 9-11) at Pacifico Yokohama, Japan and The MedTech Conference (October 15-17) at Toronto, Canada. These events offer unique opportunities for LSN to engage with key players in the life sciences and healthcare sectors, fostering new partnerships and supporting innovative startups in their fundraising efforts.

BioJapan is a premier hybrid partnering event that brings together key industry leaders in the life sciences & healthcare sectors across the globe, and Life Science Nation has been participating in this conference for many consecutive years to foster relationships with various startups, investors, pharmaceuticals, bioclusters, and more. In this year’s BioJapan, Claire Jeong, VP of Investor Research, Asia BD, will be representing Life Science Nation on a seminar organized by Life Science Incubation Council covering the theme of “how life science startups can create value with global partners”, along with speakers from MedCity (UK), BioQuebec (Canada), and Newsight Tech Angels (Japan). This seminar will take place on the last day of BioJapan, on Friday, October 11, 3:35 – 4:35pm. Meet with Claire in BioJapan.

The MedTech Conference presented by AdvaMed, will bring together thousands of industry executives and global innovators throughout the medical device, diagnostics, and digital technologies sectors. LSN will be located at Booth 1116 and looks forward to connecting with some of the industry’s most innovative companies to share how they can leverage the life science ecosystem to effectively launch their own global fundraising campaign. Meet with us at LSN booth in The MedTech Conference.

RESI-London-2024-1100px

RESI-SF-2025-Banner-1100px

JPM 101

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

Are you a JPM newbie? Will JPM 2025, from Jan. 13 – 16, be (or potentially be) your first or second JPM? JPM, short for the J.P. Morgan Healthcare Conference, is the largest life sciences investment and business development event in the world, attracting an estimated 30K – 40K ecosystem players to San Francisco every January, leaning toward a biotech focus. Let’s be clear: the majority of industry professionals descending on the Bay area do not attend the actual conference, which is an invitation-only event. In fact, the majority of partnering happens in the ecosystem that’s evolved around the conference over the last 40+ years. If someone asks you if you’re “going to JPM”, they are asking if you’ll be running around town taking partnering meetings, not if you’re attending the actual conference. That said, let’s breakdown what happens in the life science gathering that’s blossomed around the conference:

  • Pharmas, larger investors, IR firms and larger service providers rent out hotel rooms or ballrooms and convert them into partnering meeting space, where they have BD meetings. Pharma BD meetings at JPM are rumored to be more ‘high level’ than at the major biotech conventions, sometimes featuring the CEO and resulting in new deals. One of the most unique pharma partnering spaces is the Roche/Genentech area in the atrium of the Marriott Marquis, right upstairs from the RESI JPM conference.
  • There are three primary partnering conferences that generally require paid registration. Among them is RESI JPM. Though the value propositions of these events have some overlap, they’ve traditionally filled different needs.
    • RESI JPM focused on early-stage companies (discovery to phase 2) and investors (seed to series B), and featured partnering, pitching, panels, workshops and meals.
    • One of the others is focused on somewhat later stage companies (preclinical and later) and investors spanning private to public markets, and also featured partnering, pitching, panels, workshops and meals.
    • The final one is focused on providing easily accessible and flexible partnering meeting space for anyone who needs it, coupled with a partnering system to allow meeting scheduling and outreach.
  • There are other niche-specific conferences, mini-conferences, and partnering conferences that are either free or require a small fee (under $100).
  • There are numerous evening receptions hosted by a multitude of different companies and organizations. Most of these are free to attend, and some are invite-only.
  • There are numerous daytime events, again hosted by a multitude of entities, that are generally free to attend, though some require a nominal fee and some are invite-only. These include athletic events such as ‘fun runs’, networking breakfasts, meet & greets, presentation forums, workshops and more.
  • Hotel lobbies, especially those of the major hotels like the Marriott Marquis and Hilton Union Square, get turned into all-day impromptu meeting and gathering forums
  • Serendipitous meetings: part of the magic of JPM is downtown San Francisco becomes a place where you are bound to have impromptu meetings with people you literally bump into, from 7am to 1am, or even 2am.

While all this sounds very exciting, you may be scratching your head wondering, as a JPM newbie, “how do I participate in all this”?

  • To participate in the partnering meetings that take place all over downtown San Francisco, you must reach out to your potential partners from now until January to arrange the meetings. Remember to leave at least 20 minutes between meetings! If you are looking for investors or licensing partners to meet with, set up a call with us by emailing for some complimentary guidance on those who would be a good it for your company.
  • To register for RESI JPM, click here. Register for the other major JPM ecosystem conferences at their respective websites.
  • For the rest of the happenings at JPM along with a list of companies presenting at the actual JP Morgan Healthcare Conference, along with details on how to register for the events, whether free or paid, tune into our JPM page, which will go live the beginning of November. It’s worth mentioning that there are a bevy of events on Sunday, so we recommend you arrive Sunday the 12th morning or afternoon.

Finally, many consider the biggest obstacle about JPM to be the price of hotels, which can be over $1000/night even for hotels normally considered to be inexpensive. If this exceeds your budget, we recommend checking AirBnB or staying at a hotel that’s a few miles away (3 – 4 BART stops). A 20-minute train ride or a 15-minute Uber can save you a thousand dollars a night.

If you’re a JPM beginner, we’re happy to help you on your JPM journey. Contact us at RESI@Lifesciencenation.com.

RESI-London-2024-1100px

RESI-SF-2025-Banner-1100px

RESI Boston Innovator’s Pitch Challenge Winners 

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

At RESI Boston 2024, 56 innovative companies participated in the Innovator’s Pitch Challenge (IPC), providing a unique platform for early-stage life science and healthcare companies to present their technologies and connect with potential investors.

The IPC finalists delivered 4-minute pitches and a 9-minute interactive Q&A session with a panel of investor judges. In addition, each participating company showcased its technology at its personalized table space in the RESI Exhibition Hall, creating further opportunities for engagement.

The Innovator’s Pitch Challenge features a distinctive voting system where registered RESI attendees—including startup executives, early-stage investors, and industry experts – ‘invest’ in their favorite IPC companies using RESI cash provided at check-in. Attendees based their decisions on the companies’ presentations and pitch performances.

For those interested in participating in the next Innovator’s Pitch Challenge, applications are now open for RESI London 2024 and RESI JPM 2025. Early application is encouraged as spots are filled on a rolling basis.

Life Science Nation is proud to announce the top three winners of RESI Boston 2024’s Innovator’s Pitch Challenge:

1st Place: Amplified Sciences

RESI-Boston-1st-PlaceMax Braht, Business Development Manager, Life Science Nation | Diana Caldwell, MBA,CEO and Co-Founder, Amplified Sciences | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series


2nd Place: EYWA Biotech

RESI-Boston-2nd-PlaceGreg Mannix, VP, International Business Development, Life Science Nation | Victoria Costa Paz, CEO and Co-Founder, EYWA Biotech | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series


3rd Place: RadioClash

RESI-Boston-3rd-PlaceMomo Yamamoto, Investor Research Analyst, Life Science Nation | John Qiao, Founder and CEO, RadioClash | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

The 56 companies were assigned to 14 different sessions throughout the day, with 4 companies grouped together based on similar sector or technology. These companies were evaluated by a panel of judges, and the following companies were the highest scorers. This attests to the high quality of their pitch, ability to answer questions, and clearly deliver their value proposition.

Judges Picks:

IPC-Judge-Picks

RESI-London-2024-1100px

RESI-SF-2025-Banner-1100px